BioSpace News Archive

Alvotech and Kashiv Biosciences LLC announced that they have entered into an exclusive licensing agreement for AVT23, a proposed biosimilar to Xolair®, which is currently in clinical development.

According to the instructions for the Nomination Committee of Immunovia AB that were adopted at the Annual General Meeting on May 26, 2023, the Nomination Committee shall consist of four members.

ALX Oncology Holdings Inc. announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s CD47 blocking therapeutic, in combination with trastuzumab, CYRAMZA® and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer.

NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that it will present data from a Phase I/IIa clinical trial of NMD670 in patients with myasthenia gravis (MG) in a poster presentation at the 28th International Annual Congress of the World MuscleSociety.

Sunstone Therapies today announces the expansion of its MDMA-assisted Dyad Study to include 20 dyads (pairs of participants).

First Wave BioPharma, Inc. today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation at the 2023 Roth Healthcare Opportunities Conference taking place October 12, 2023, in New York.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Shephard (Shep) Mpofu, MD, MRCP, FRCP as Senior Vice President of Development.

Medicenna Therapeutics Corp. today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.

A high-potency ginger extract was shown to help mitigate menstrual cramping in a new clinical study.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease.